Skip to main content

Table 2 Tuberculosis incidence density stratified by clinical and immunological characteristics of PLHIV on chronic HIV care at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018 (N = 494)

From: Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study

CharacteristicsFrequency (n = 494)Percent (%)Person yearTB (n = 62)Censored (n = 432)TB IR per 100 PY
(95% CI)
Past TB treatment
 Yes142.8336.146816.60 (7.46, 36.95)
 No48097.17964.08564245.81 (4.47, 7.55)
Baseline WHO clinical staging
 Stage I21944.33396.8172121.77 (0.84, 3.70)
 Stage II12425.10294.6761182.04 (0.91, 4.53)
 Stage III12224.70263.23378514.06 (10.18, 19.40)
 Stage IV295.8745.51121726.37 (14.97, 46.43)
Baseline CD4 count (cells/μl)
  < 50387.6979.93152318.77 (11.31, 31.13)
 50 – < 1005110.3295.09183318.93 (11.93, 30.04)
 100–2007515.18170.3114618.22 (4.87, 13.88)
 201–35012324.90268.43101133.73 (2.00, 6.92)
  ≥ 35020741.90386.4652021.29 (0.54, 3.11)
Baseline hemoglobin level (g/dl)
  < 1013527.33257.82528320.17 (15.37, 26.47)
  ≥ 1035972.67742.41103491.35 (0.72, 2.50)
Baseline body mass index (kg/m2)
  < 18.516132.59288.034711416.32 (12.26, 21.72)
  ≥ 18.533367.41712.19153182.11 (1.27, 3.49)
Baseline functional status
 Working39279.35832.36153771.80 (1.09, 2.99)
Ambulate/bedridden10220.65167.86475528.00 (21.04, 37.27)
Past opportunistic infection (OIs)
 Yes7915.99215.1718618.37 (5.27,13.28)
 No41584.01785.05443715.60 (4.17, 7.53)
ART adherence
 Good36774.29763.97153521.96 (1.18, 3.25)
 Fair/poor12725.71236.25478019.89 (14.95, 26.48)
Took IPT during follow up
 Yes19539.47406.9051901.23 (0.51, 2.95)
 No29960.53593.32572429.61 (7.41, 12.45)
Total year of follow up
  ≤ 1 year16934.2173.984312658.13 (43.11, 78.37)
  > 1 - < 3 years18036.44353.47111693.11 (1.72, 5.62)
 3–5 years14529.35572.7881371.39 (0.69, 2.79)